High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study—Protocol Design and Demography of the First 100 Patients

Autor: Olga Soukhomovskaia, Marco Valgimigli, Giordano Cicchitelli, Alessandro Bettini, Roberto Ferrari, Dario Barbieri, Gianfranco Percoco, Gianluca Campo, Patrizia Malagutti, Giovanni Parrinello, L. Ansani, Gabriele Guardigli, Fabrizio Ferrari
Rok vydání: 2004
Předmět:
Male
Bare-metal stent
Time Factors
Platelet Aggregation
Abciximab
medicine.medical_treatment
Myocardial Infarction
Electrocardiography
Sirolimus eluting stents
Clinical Protocols
Restenosis
Pharmacology (medical)
Myocardial infarction
health care economics and organizations
Drug Implants
Antibodies
Monoclonal
General Medicine
Tirofiban
Middle Aged
primary percutaneous coronary intervention
Treatment Outcome
surgical procedures
operative
high dose Bolus tirofiban
Italy
Cardiology
Drug Therapy
Combination
Female
Stents
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
Injections
Coronary Restenosis
Immunoglobulin Fab Fragments
Angioplasty
Internal medicine
medicine
Humans
cardiovascular diseases
Sirolimus
Pharmacology
business.industry
Stent
equipment and supplies
medicine.disease
Surgery
Tyrosine
Myocardial infarction diagnosis
business
Forecasting
Zdroj: Cardiovascular Drugs and Therapy. 18:225-230
ISSN: 0920-3206
DOI: 10.1023/b:card.0000033644.91126.f7
Popis: Primary bare metal stenting and abciximab infusion are currently considered the best available reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). Sirolimus eluting stents (SES), compared to bare metal stent (BMS), greatly reduce the incidence of binary restenosis and target vessel revascularisation (TVR), but their use on a routine basis results in a significant increase in medical costs. With current European list prices, the use of tirofiban instead of abciximab would save enough money to absorb the difference between SES and BMS.To assess whether in patients with STEMI the combination of SES with high dose bolus (HDB) tirofiban results in a similar incidence of major cardiovascular events (MACE) but in a lower binary restenosis rate after six months compared to BMS and abciximab.160 patients are required to satisfy the primary composite end-point, including MACE and binary restenosis. The study is ongoing: the current paper focuses on the methodology and demography of the first 100 patients so far enrolled. Patients randomised to HDB tirofiban (n = 50, mean age: 62 +/- 12, 40 males) and abciximab (n = 50, mean age: 63 +/- 12, 38 males) do not differ for medical history, presentation profile, medications at discharge, angiographic profile and creatine-kinase MB-fraction at peak.The results of the trial will be available by the end of 2004: they will be crucial for the cardiologists to know whether the gold standard for AMI treatment should be reconsidered after the introduction of SES into the clinical practice.
Databáze: OpenAIRE
Externí odkaz: